請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58517
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 鄭永銘(Yung-Ming Jeng) | |
dc.contributor.author | Hsien-Ting Chiang | en |
dc.contributor.author | 江賢梃 | zh_TW |
dc.date.accessioned | 2021-06-16T08:18:12Z | - |
dc.date.available | 2020-08-26 | |
dc.date.copyright | 2020-08-26 | |
dc.date.issued | 2020 | |
dc.date.submitted | 2020-07-21 | |
dc.identifier.citation | 6. Reference [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7‐30. [2] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646–74. [3] Lin X, Zhao Y, Song WM, et al. Molecular classification and prediction in GC. Comput Struct Biotechnol J 2015;13:448–58. [4] Ajani JA, Lee J, Sano T, Janjigian YY, Fan D, Song S. Gastric adenocarcinoma. Nat Rev Dis Primers. 2017 Jun 1; 3():17036. [5] Cristescu R, Lee J, Nebozhyn M, Kim KM, Ting JC, Wong SS, Liu J, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. A Nat Med. 2015 May; 21(5):449-56. [6] Comprehensive molecular characterization of gastric adenocarcinoma. Cancer Genome Atlas Research Network. Nature. 2014 Sep 11; 513(7517):202-9. [7] Bae YS, Kim H, Noh SH, Kim H. Usefulness of Immunohistochemistry for Microsatellite Instability Screening in Gastric Cancer. Gut and Liver. 2015;9(5):629–35. 10.5009/gnl15133 [8] Cristescu R, Lee J, Nebozhyn M, Kim K-M, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21(5):449–56. [9] Teresa S Kim, Edaise da Silva, Daniel G Coit, Laura H Tang. Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype. Am J Surg Pathol. 2019 Jun;43(6):851-860. [10] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357:539–545. [11] Spill F., Reynolds D.S., Kamm R.D., Zaman M.H. Impact of the physical microenvironment on tumor progression and metastasis. Curr. Opin. Biotechnol. 2016;40:41–48. [12] Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature. 2008;454:436–444. [13] Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. [14] Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005;7:211–217. [15] Mantovani A. Molecular pathways linking inflammation and cancer. Curr Mol Med. 2010 Jun;10(4):369-73. [16] Koehne CH, Dubois RN. COX-2 inhibition and colorectal cancer. Semin Oncol. 2004;31:12–21. [17] Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. (1998) 188:2357–68. [18] Piersma SJ, Jordanova ES, van Poelgeest MI, Kwappenberg KM, van der Hulst JM, Drijfhout JW, et al. . High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. (2007) 67:354–61. [19] Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2010) 29:1093–102. [20] Hanahan D, Coussens LM (March 2012). 'Accessories to the crime: functions of cells recruited to the tumor microenvironment'. Cancer Cell. 21 (3): 309–22. [21] Coussens LM, Zitvogel L, Palucka AK (January 2013). 'Neutralizing tumor-promoting chronic inflammation: a magic bullet?'. Science. 339 (6117): 286–91. [22] Bianchini G, Gianni L. The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol. (2014) 15:e58–68. [23] Denkert C, Loibl S, Noske A, Roller M, Muller BM, Komor M, et al. . Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. (2010) 28:105–13. [24] Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, et al. . Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer (2017) 20:407–15. [25] Dai C, Geng R, Wang C, Wong A, Qing M, Hu J, et al. . Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol Oncol. (2016) 10:1551–8. [26] Denkert C, von Minckwitz G, Brase JC, Sinn BV, Gade S, Kronenwett R, et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol. (2015) 33:983–91. [27] Denkert C, Wienert S, Poterie A, Loibl S, Budczies J, Badve S, et al. Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Mod Pathol. (2016) 29:1155–64. [28] Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat Immunol. (2008) 9:503–10. 10.1038/ni1582 [29] Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S (January 2011). 'Innate or adaptive immunity? The example of natural killer cells'. Science. 331 (6013): 44–9. [30] Wu Y, Kuang DM, Pan WD, Wan YL, Lao XM, Wang D, Li XF, Zheng L. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology 2013; 57:1107-16; PMID:23225218 [31] Tuanjie Li, Qi Zhang, Yuming Jiang, Jiang Yu, Yanfeng Hu, Tingyu Mou, Guihua Chen, (August 2015). 'Gastric cancer cells inhibit natural killer cell proliferation and induce apoptosis via prostaglandin E2'. Oncoimmunology. 5(2): e1069936. [32] Chen JP, Yang J, Jiang JT, Zhuang Y, He W. PD-L1 expression is a prognostic of dendritic cells and natural killer cells were decreased in gastric cancer. Int J Clin Exp Pathol. (2014) 7:8304–11. [33] Erwig, L.-P.; Henson, P.M. Clearance of apoptotic cells by phagocytes. Cell Death Differ. 2008, 15, 243–250. [34] 'Regenerative Medicine Partnership in Education'. Archived from the original on 25 April 2015. Retrieved 7 May 2015. [35] Murray, P.J.; Wynn, T.A. Protective and pathogenic functions of macrophage subsets. Nat. Rev. Immunol. 2011, 11, 723–737. [36] Biswas, S.K.; Allavena, P.; Mantovani, A. Tumor-associated macrophages: Functional diversity, clinical significance, and open questions. Semin. Immunopathol. 2013, 35, 585–600. [37] Murphy, Kenneth (2012). Janeway's Immunobiology (8th ed.). New York: Garland Science. ISBN 9780815342434. [38] S.M. Mahmoud, A.H. Lee, E.C. Paish, R.D. Macmillan, I.O. Ellis, A.R. Green The prognostic significance of B lymphocytes in invasive carcinoma of the breast Breast Cancer Res Treat, 132 (2012), pp. 545-553 [39] K.I. Al-Shibli, T. Donnem, S. Al-Saad, M. Persson, R.M. Bremnes, L.T. Busund Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res, 14 (2008), pp. 5220-5227 [40] J.S. Nielsen, R.A. Sahota, K. Milne, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res, 18 (2012), pp. 3281-3292 [41] Badawy AA, Bano S (January 2016). 'Tryptophan Metabolism in Rat Liver After Administration of Tryptophan, Kynurenine Metabolites, and Kynureninase Inhibitors'. International Journal of Tryptophan Research. 9: 51–65. [42] Prendergast GC, Metz R, Muller AJ, Merlo LM, Mandik-Nayak L (2014-11-20). 'IDO2 in Immunomodulation and Autoimmune Disease'. Frontiers in Immunology. 5: 585. doi:10.3389/fimmu.2014.00585. PMC 4238401. PMID 25477879 [43] Thackray SJ, Mowat CG, Chapman SK. Exploring the mechanism of tryptophan 2,3‐dioxygenase. Biochem Soc Trans. 2008;36:1120‐1123. [44] Munn DH, Mellor AL (March 2013). 'Indoleamine 2,3 dioxygenase and metabolic control of immune responses'. Trends in Immunology. 34 (3): 137–43. [45] Maleki VS, Rytelewski M, Figueredo R, et al. Indoleamine 2,3‐ dioxygenase mediates immune‐independent human tumor cell resistance to olaparib, gamma radiation, and cisplatin. Oncotarget. 2014;5:2778‐2791. [46] Munn DH, Mellor AL. Indoleamine 2,3‐dioxygenase and tumor‐ induced tolerance. J Clin Invest. 2007;117:1147‐1154. [47] Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974‐1982. [48] Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450‐461. [49] Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704. [50] Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439:682–687. [51] Wherry EJ. T cell exhaustion. Nature immunology. 2011;12:492–499. [52] Shi L, Chen S, Yang L, Li Y. The role of PD‐1 and PD‐L1 in T‐cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74. [53] Yarchoan M, Johnson BA 3rd, Lutz ER, Laheru DA, Jaffee EM. Targeting neoantigens to augment antitumour immunity. Nat Rev Cancer. 2017;17:209‐222. [54] Cho J, Lee J, Bang H, et al. Programmed cell death-ligand 1 expression predicts survival in patients with gastric carcinoma with microsatellite instability. Oncotarget. 2017;8:13320. [55] Maher A Sughayer, Tamara Z Dabbagh, Abdelkader H Battah. PD-L1 Expression Is a Favorable Prognostic Marker in Gastric Carcinoma. Immunohistochemistry Molecular Morphology: 2020, 32205740. [56] Safinia N, Leech J, Hernandez‐Fuentes M, Lechler R, Lombardi G. Promoting transplantation tolerance; adoptive regulatory T cell therapy. Clin Exp Immunol. 2013;172:158‐168. [57] Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6:295‐307. [58] Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci USA. 2005;102:5138–5143. [59] Marshall EA, Ng KW, Kung S, et al. Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. Mol Cancer. 2016;15:67 [60] G-F Ma, Q Miao, Y-M Liu, H Gao, J-J Lian, et al. High FoxP3 expression in tumour cells predicts better survival in gastric cancer and its role in tumour microenvironment. Br J Cancer. 2014 Mar 18; 110(6): 1552–1560. [61] Li Z, Ju Z, Frieri M. The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity. Allergy Asthma Proc. 2013;34(1):21–26. [62] Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ (January 2009). 'Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection'. Nature Immunology. 10 (1): 29–37. [63] Li Z, Ju Z, Frieri M. The T-cell immunoglobulin and mucin domain (Tim) gene family in asthma, allergy, and autoimmunity. Allergy Asthma Proc. 2013;34(1):21–26. [64] Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature. 2002;415(6871):536–541. [65] Phong BL, Avery L, Sumpter TL, et al. Tim-3 enhances FcεRI-proximal signaling to modulate mast cell activation. J Exp Med. 2015;212(13):2289–2304. [66] Wada J, Kanwar YS (February 1997). 'Identification and characterization of galectin-9, a novel beta-galactoside-binding mammalian lectin'. The Journal of Biological Chemistry. 272 (9): 6078–86. [67] Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK (December 2005). 'The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity'. Nature Immunology. 6 (12): 1245–52. [68] Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE, Ansell SM (April 2012). 'IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma'. The Journal of Clinical Investigation. 122 (4): 1271–82. [69] Cheng G, Li M, Wu J, et al. Expression of Tim-3 in gastric cancer tissue and its relationship with prognosis. Int J Clin Exp Pathol. 2015;8(8):9452–9457. [70] Jiang J, Jin MS, Kong F, et al. Decreased galectin-9 and increased Tim-3 expression are related to poor prognosis in gastric cancer. PLoS One. 2013;8(12): e81799. [71] Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, et al. (February 2016). 'Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints'. Nature Communications. 7: 10501. [72] Rousalova I, Krepela E (December 2010). 'Granzyme B-induced apoptosis in cancer cells and its regulation (review)'. International Journal of Oncology. 37 (6): 1361–78. [73] Podack ER. Execution and suicide: cytotoxic lymphocytes enforce Draconian laws through separate molecular pathways. Curr Opin Immunol. 1995;7(1):11–6. [74] Nagata S. Apoptosis by death factor. Cell. 1997;88(3):355–65. [75] I.S. Afonina, G.A. Tynan, S.E. Logue, S.P. Cullen, M. Bots, A.U. Luthi, E.P. Reeves, N.G. McElvaney, J.P. Medema, E.C. Lavelle, S.J. Martin. Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1α. Mol. Cell, 44 (2) (2011), pp. 265-278 [76] Afonina IS, Cullen SP, Martin SJ (May 2010). 'Cytotoxic and non-cytotoxic roles of the CTL/NK protease granzyme B'. Immunological Reviews. 235 (1): 105–16. [77] Waterhouse NJ, Sedelies KA, Trapani JA (February 2006). 'Role of Bid-induced mitochondrial outer membrane permeabilization in granzyme B-induced apoptosis'. Immunology and Cell Biology. 84 (1): 72–8. [78] Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513: 202–209. [79] Sohn BH, Hwang JE, Jang HJ, Lee HS, Oh SC, Shim JJ et al (2017) Clinical significance of four molecular subtypes of gastric cancer identified by the cancer genome atlas project. Clin Cancer Res 1(23):4441–4449. [80] M.C. Camargo, W.-H. Kim, A.M. Chiaravalli, K.-M. Kim, A.H. Corvalan, K. Matsuo, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut , 63 (2) (2014), pp. 236-243 [81] L. Zhu, Z. Li, Y. Wang, C. Zhang, Y. Liu, X. Qu. Microsatellite instability and survival in gastric cancer: a systematic review and meta-analysis. Mol Clin Oncol, 3 (3) (2015), pp. 699-705 [82] X. Li, W.K.K. Wu, R. Xing, S.H. Wong, Y. Liu, X. Fang, et al. Distinct subtypes of gastric cancer defined by molecular characterization include novel mutational signatures with prognostic capability. Cancer Res, 76 (7) (2016), pp. 1724-1732 [83] Maleki SS, Röcken C. Chromosomal Instability in Gastric Cancer Biology. Neoplasia. 2017;19:412-20. [84] Nam HJ, Chae S, Jang SH, Cho H, Lee JH. The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability. Carcinogenesis. 2010;31:1531-40. [85] Bou-Nader M, Caruso S, Donne R, Celton-Morizur S, Calderaro J, Gentric G, Cadoux M, L'Hermitte A, Klein C, Guilbert T, et al. Polyploidy spectrum: A new marker in HCC classification. Gut. 2019;(pii) gutjnl-2018-318021. [86] van Beek J, zur Hausen A, Snel SN, et al. Morphological evidence of an activated cytotoxic T-cell infiltrate in EBV-positive gastric carcinoma preventing lymph node metastases. Am J Surg Pathol. 2006;30:59–65. [87] Ma C, Patel K, Singhi AD, et al. Programmed death-ligand 1 expression is common in gastric cancer associated with Epstein Barr Virus or microsatellite instability.Am J Surg Pathol. 2016;40:1496–1506. [88] Ying L, Yan F, Meng Q, et al. PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers. Oncoimmunology. 2018;7:e1433520. [89] Senovilla L, Vacchelli E, Galon J, Adjemian S, Eggermont A, Fridman WH, Sautès-Fridman C, Ma Y, Tartour E, Zitvogel L et al.. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 2012; 1:1323-43; PMID:23243596 [90] Nakano O, Sato M, Naito Y, Suzuki K, Orikasa S, Aizawa M, Suzuki Y, Shintaku I, Nagura H, Ohtani H. Proliferative activity of intratumoral CD8(+) T-lymphocytes as a prognostic factor in human renal cell carcinoma: clinicopathologic demonstration of antitumor immunity. Cancer Res. 2001;61:5132–5136. [91] Schumacher K, Haensch W, Roefzaad C, Schlag PM. Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res. 2001;61:3932–3936. [92] Hornyák L, Dobos N, Koncz G, et al. The role of indoleamine-2, 3-dioxygenase in cancer development, diagnostics, and therapy. Front Immunol. 2018;9:151. [93] Liu H, Shen Z, Wang Z, et al. Increased expression of IDO associates with poor postoperative clinical outcome of patients with gastric adenocarcinoma. Sci Rep. 2016;6:21319. [94] Nishi M, Yoshikawa K, Higashijima J, et al. The impact of indoleamine 2, 3-dioxygenase (IDO) expression on stage III gastric cancer. Anticancer Res. 2018;38:3387–3392. [95] Kim JW, Nam KH, Ahn SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 2016;19:42–52. [96] Shaolong Li, Xue Han, Ning Lyu, et al. Mechanism and prognostic value of indoleamine 2,3‐dioxygenase 1 expressed in hepatocellular carcinoma. Cancer Sci. 2018; 109(12): 3726–3736. [97] Tumor infiltrating T lymphocytes expressing FoxP3, CCR7 or PD-1 predict the outcome of prostate cancer patients subjected to salvage radiotherapy after biochemical relapse. Cancer Biol. Ther., 17 (2016), pp. 1213-1220 [98] Haas M, Dimmler A, Hohenberger W, et al. Stromal regulatory T-cells are associated with a favourable prognosis in gastric cancer of the cardia. BMC Gastroenterol. 2009;9:65. [99] Wang J, Reiss KA, Khatri R, Jaffee E, Laheru D. Immune therapy in GI malignancies: a review. J Clin Oncol. 2015;33:1745–1753. [100] Perrone G, Ruffini PA, Catalano V, et al. Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer. Eur J Cancer. 2008;44:1875–1882. [101] Zhuang X, Zhang X, Xia X, Zhang C, Liang X, Gao L, Ma C. Ectopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLC. Am J Clin Pathol. 2012;137:978–985. [102] Cao Y, Zhou X, Huang X, Li Q, Gao L, Jiang L, Huang M, Zhou J. Tim-3 expression in cervical cancer promotes tumor metastasis. PLoS One. 2013;8:e53834. [103] Byun KD, Hwang HJ, Park KJ, Kim MC, Cho SH, Ju MH, et al. T-cell immunoglobulin mucin 3 expression on tumor infiltrating lymphocytes as a positive prognosticator in triple-negative breast cancer. J Breast Cancer. 2018;21:406–414. [104] Ma W, Gilligan BM, Yuan J, et al. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.J Hematol Oncol. 2016;9:47. [105] Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy.Clin Cancer Res. 2014;20:5064–5074. [106] Kim JW, Nam KH, Ahn SH, et al. Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. Gastric Cancer. 2016;19:42–52. [107] Chang H, Jung WY, Kang Y, et al. Programmed death-ligand 1 expression in gastric adenocarcinoma is a poor prognostic factor in a high CD8+ tumor infiltrating lymphocytes group. Oncotarget. 2016;7:80426–80434. [108] Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013;5:200 ra116. 10.1126. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/58517 | - |
dc.description.abstract | 背景 眾所周知,胃癌是一種複雜,且異質性的實體,具有不同的組織學類型、分子特徵和生物學行為。根據基因組數據,它可以細分為四種分子類型:EBV病毒(EBV)陽性,微衛星不穩定性(MSI),基因組穩定(GS)和染色體不穩定性(CI)。儘管新靶標治療策略基於胃癌相關的分子機制改善了治療效果,但預後並未明顯改善。這四種類型的免疫微環境是否不同以及免疫狀態是否可用於預測患者的預後仍有待闡明。因此,目前迫切需要開發新的預後生物標誌物。 方法 這項研究旨在評估TCGA分類對免疫狀況的功能影響,並評估免疫調節蛋白在胃癌患者預後中的表達。在本研究中,將台灣大學醫院胃癌患者的腫瘤組織構建成組織陣列進行分析。進行錯配修復蛋白的免疫染色和EBV原位雜交,分別檢測微衛星不穩定性和EBV感染。使用福爾馬林固定石蠟包埋的樣品進行DNA流式細胞儀鑑定異常DNA含量。免疫組織化學測定法用於IDO1、Granzyme B、FoxP3、PD-1、PD-L1、Tim-3和發炎性細胞標記物。通過使用Vectra Polaris自動定量病理成像系統將載玻片掃描為多光譜圖像。細胞計數由模式識別軟件inForm Tissue Finder確定。生存分析的臨界點由X-tile軟體決定。 結果 我們發現EBV陽性和MSI患者的復發生存和總體生存比CI和GS患者更長。此外,彌散型CI患者的復發和死亡頻率比GS和腸型CI患者更高。接下來,我們發現在胃癌的四種生物學亞型中,EBV陽性和MSI腫瘤的免疫浸潤最豐富。生存分析表明,免疫調節蛋白(包括IDO1、Granzyme B、FoxP3、PD-1、PD-L1、Tim-3)的高表達在復發生存和總體生存方面均具有良好的預後。然而,只有高CD3 + T細胞、CD4 + T細胞、CD8 + T細胞和CD20 + B譜系細胞預後良好,而CD56 + NK細胞、CD68 +巨噬細胞和CD206 +巨噬細胞的計數在總體生存和復發生存中均無意義。此外,發現IDO1是復發生存或總體生存的獨立預後因素。在III和IV期患者中,僅IDO1的表達水平與預後顯著相關(P <0.05)。 結論 總之,我們發現免疫調節因子在胃癌中的預後意義。這些結果表明,免疫調節因子可能是潛在的預測指標,並可能指導胃癌免疫檢查點治療劑的選擇。 | zh_TW |
dc.description.abstract | Abstract Background It is well known that gastric cancer is an intricate, heterogeneous entity with diverse histological types, molecular profiles, and biological behaviors. It can be sub-classified into four molecular types based on the genome data: Epstein-Barr virus (EBV)-positive, microsatellite instability (MSI), genomically stable (GS), and chromosomal instability (CI). Although new target therapeutic strategies based on molecular mechanisms related to gastric cancer have improved treatment outcomes, prognoses have not improved significantly. Whether these four types have different immune microenvironment and whether the immune status can be used to predict patient prognosis are still need to be illuminated. Hence, new prognostic biomarkers development is urgently needed. Methods This study was aimed to evaluate the functional impact of TCGA classification on immune contexture and assess the expression of immune regulatory proteins in the prognostic role in gastric cancer patients. In our study, tumor tissues of gastric carcinomas patients from National Taiwan University Hospital were constructed into tissue array for analysis. Immunostaining for mismatch-repair proteins and EBV in situ hybridization was conducted to detect microsatellite instability and EBV infection, respectively. DNA flow cytometry was conducted to identify abnormal DNA content using formalin-fixed paraffin-embedded samples. Immunohistochemistry assay was employed for IDO1, Granzyme B, FoxP3, PD-1, PD-L1, Tim-3 and inflammatory cell markers. The slides with be scanned to multispectral image by using Vectra Polaris Automated Quantitative Pathology Imaging System. Cell counts were determined by the pattern recognition software, inForm Tissue Finder. Cut off points of survival analysis were decided by X-tile software. Results We found that EBV-positive and MSI patients had a longer 5-year recurrence-free survival and 5-year overall survival than CI and GS patients. Besides, diffuse type CI patients had more frequent recurrence and death than those with GS and intestinal type CI patients did. Next, we discovered that among the 4 biological subtypes of gastric cancer, EBV-positive and MSI tumors had the most abundant immune infiltrate. Survival analysis indicated that high expression of immune regulatory proteins, including IDO1, Granzyme B, FoxP3, PD-1, PD-L1, Tim-3, yielded strongly favorable prognosis in both recurrence-free survival and overall survival. However, only high CD3+T cell, CD4+T cell, CD8+T cell, and CD20+ B lineage cell generated favorable prognosis, whereas the count of CD56+ NK cells, CD68+ macrophages and CD206+ macrophages showed no significance in both overall survival and recurrence-free survival. Furthermore, IDO1 was found to be an independent favorable prognostic factor for both recurrence-free survival or overall survival. In stage III and IV patients, only the expression level of IDO1 was significantly correlated with prognosis (P < 0.05). Conclusions In summary, we found that the prognostic significance of immune regulatory factors in gastric cancer. These results indicate that immune regulatory factors might be a potential predictive marker, and may guide the selection of immune checkpoint therapeutics in gastric carcinoma. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T08:18:12Z (GMT). No. of bitstreams: 1 U0001-1307202009573100.pdf: 3023666 bytes, checksum: 59d151f12268482e694a9ad830500a87 (MD5) Previous issue date: 2020 | en |
dc.description.tableofcontents | CONTENTS 口試委員會審定書 i 謝辭 ii 中文摘要 iii ABSTRACT v CONTENTS vii 1. Introduction 1 1.1 Gastric cancer 1 1.2 Lauren classification 2 1.3 TCGA classification 2 1.4 Tumor microenvironment 3 1.5 Tumor-infiltrating lymphocytes 4 1.6 Natural killer cells 5 1.7 Macrophages 5 1.8 B cell 6 1.9 Indoleamine 2,3-dioxygenase 1 (IDO1) 7 1.10 PD-1 PD-L1 8 1.11 Foxp3. 9 1.12 Tim-3. 10 1.13 Granzyme B. 10 1.14 Aim of this study. 11 2.Materials and Methods 12 2.1 Tissue Specimens 12 2.2 Morphologic Review 12 2.3 Tissue Arrays and Immunohistochemistry 13 2.4 In-Situ Hybridization 14 2.5 DNA Flow Cytometry 14 2.6 Multispectral Imaging 15 2.7 Selection of Cutoff Score 16 2.8 Statistical Analysis 16 3. Results 17 3.1 The procedure of automated quantitative pathology imaging system and inForm image analysis 17 3.2 Survival analysis according to the TCGA (The Cancer Genome Atlas) molecular classification Lauren's classification in GC. 18 3.3 CI and GS subtype tumors have less infiltration of immune cells 19 3.4 Survival analysis according to the count of tumor-infiltrating lymphocytes (TILs) 19 3.5 Prognostic value of immune regulatory molecules in GC 20 3.6 IDO1 expression is an independent prognostic factor for GC patients 21 4. Discussion 22 4.1 Combined molecular and histologic classification predict the prognosis of gastric cancer patients 22 4.2 CI and GS subtype patients had less infiltration of immune cells 23 4.3 Activation of adaptive immune system was more significant than activation of innate immune system in predicting prognosis 24 4.4 Immune regulatory molecules were strong predictor of prognosis of GC patients 25 4.5 Limitations 27 4.6 Conclusions 28 5. Figures and Tables 29 6. Reference 44 | |
dc.language.iso | zh-TW | |
dc.title | 胃癌中之免疫反應及免疫調節因子表現:與腫瘤亞型及病患預後相關 | zh_TW |
dc.title | Immune Response and expression of immunoregulatory molecules in gastric cancer: correlation with tumor subtype and patient prognosis | en |
dc.type | Thesis | |
dc.date.schoolyear | 108-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 袁瑞晃(Ray-Hwang Yuan),蔡佳惠 (Jia-Huei Tsai) | |
dc.subject.keyword | 胃癌,腫瘤微環境,TCGA分類,免疫調節蛋白,免疫組織化學染色, | zh_TW |
dc.subject.keyword | Gastric cancer,Tumor microenvironment,TCGA classification,Immune regulatory proteins,Immunohistochemistry, | en |
dc.relation.page | 54 | |
dc.identifier.doi | 10.6342/NTU202001461 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2020-07-21 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 病理學研究所 | zh_TW |
顯示於系所單位: | 病理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
U0001-1307202009573100.pdf 目前未授權公開取用 | 2.95 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。